ScholarLens Back to search
2015•Clinical Lymphoma Myeloma & LeukemiaRequires access

Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Jesús F. San Miguel, Vania Tietsche de Moraes Hungria, Sung‐Soo Yoon, Meral Beksaç, Meletios Athanasios Dimopoulos, Ashraf Elghandour, W Wiktor-Jędrzejczak, Andreas Guenther, Thanyaphong Na Nakorn, N. Siritanaratkul, R. L. Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, J.H. Lee, Hermann Einsele, Monika Sopala, Suman Redhu, Sebastian Paul, Claudia Corrado, Florence Binlich, Paul Gerard Guy Richardson

Open publisher page 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Panobinostat, Dexamethasone, Bortezomib, Medicine, Dosing, Pharmacology, Multiple myeloma, Refractory (planetary science)

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma — Research Paper | ScholarLens